Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan

Hsieh, Chee-Ruey and Liu, Ya-Ming and Chang, Chia-Lin (2011): Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

Abstract

Although the technological change in medicine has been widely recognized as the major driver of rising healthcare costs, there is very little research that directly estimates this effect. This paper uses both a single-equation and a simultaneous equations approach to empirically investigate the interactive relationship between technological innovation and the growth of health expenditure in the context of the pharmaceutical market in Taiwan. Based on observing 182 therapeutic groups between 1997 and 2006, we find evidence to support the argument that technological innovation and health expenditure are simultaneously determined as technological innovation and the growth of health expenditure are endogenous rather than exogenous. Specifically, we find that therapeutic groups associated with higher pharmaceutical expenditure are likely to attract more new products to the market. Meanwhile, therapeutic groups with more new products are associated with higher pharmaceutical expenditures. An important implication of the paper is that the cost containment policy will not only affect the growth of health expenditure, but will also affect the progress of technological innovation in the health sector.

• Item Type: MPRA Paper
• Language: English
• Keywords: Technological innovation, new drugs, health expenditure, simultaneous equation model
• Subjects: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; I - Health, Education, and Welfare > I1 - Health > I19 - Other

References

Acemoglu, D., Linn, J.: Market size in innovation: theory and evidence from the pharmaceutical industry. Q. J. Econ. 119(3), 1049-1090 (2004)

Anindya, S.: Is health care a luxury? New evidence from OECD data. Int. J. Health Care Finance Econ. 5(2), 147-164 (2005)

Baltagi, B.H., Moscone, F.: Health care expenditure and income in the OECD reconsidered: evidence from panel data. Econ Model. 27, 804-811 (2010)

Carrion-i-Silvestre, J.L.: Health care expenditure and GDP: are they broken stationary? J. Health Econ. 24, 839-854 (2005)

Cutler, D.M., McClellan, M.: Is technological change in medicine worth it? Health Aff. 20,11-29 (2001)

Finkelstein, A.: Static and dynamic effects of health policy: evidence from the vaccine industry. Q. J. Econ. 119(2), 527-564 (2004)

Finkelstein, A.: The aggregate effects of health insurance: evidence from the introduction of Medicare. Q. J. Econ. 122(1), 1-37 (2007)

Fuchs, V. R.: Economics, values, and health care reform. Am. Econ. Rev. 86(1), 1-24 (1996)

Gerdtham, Ulf-G, JÖnsson, B.: International comparisons on health expenditure: theory, data and econometric analysis. In: Culyer, A.J., Newhouse, J.P. (eds.) Handbook of Health Economics, pp. 11-53. North Holland, Elsevier Science (2000)

Hall, R. E., Jones, C. I.: The value of life and the rise in health spending. Q. J. Econ. 122(1), 39-72 (2007)

Hausman, J.A.: Specification tests in econometrics. Econometrics 46, 1251-1271 (1978).

Kleiman, E.: The Determinants of National Outlay on Health. In: Perlman, M., (eds.) The Economics of Health and Medical Care, Macmillan, London (1974)

Lichtenberg, F. R., Virabhak, R.: Pharmaceutical Embodied Technical Progress, Longevity, and Quality of Life: Drugs as ‘Equiptment for your Health’. National Bureau of Economic Research (2002)

Lichtenberg, F. R.: Pharmaceutical innovations, mortality reduction, and economic growth. In: Murphy, K. M., Topel, R. H. (eds.) Measuring the Gains from Medical Research: An Economic Approach. University of Chicago Press (2003)

Lichtenberg, F. R.: The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int. J. Health Care Finance Econ. 5(1), 47-73 (2005)

Lichtenberg, F.R.: The quality of medical care, behavior risk factors, and longevity growth. Int. J. Health Care Finance Econ. 11, 1-34 (2011)

Liu, Y.M., Hsieh, C.R.: New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan,” Health Econ. DOI: 10.1002/hec.1724.

Liu, Y.M., Kao Yang, Y.H., Hsieh, C.R.: Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. Mimeo (2011)

Newhouse, J. P.: Medical care costs: how much welfare loss? J. Econ. Perspect. 16(3), 3-21 (1992)

Newhouse, J.P.: Medical care expenditures: a cross-national survey. J. Human Res. 12, 115-125 (1977)

Okunade, A.A., Murthy, V.N.R.: Technology as a ‘major driver’ of health care costs: a cointegration analysis of the Newhouse conjecture. J. Health Econ. 21, 147–159 (2002)

Papageorgiou, C., Savvides, A., Zachariadis, M.: International medical technology diffusion. J. Int. Econ. 72, 409-427 (2007)

Smith, S., Newhouse, J.P., Freeland, M.S.: Income, insurance and technology: why does health spending outpace economic growth? Health Aff. 28(5), 1276-1284 (2009)

Staiger, D., Stock, J.H.: Instrumental variables with weak instruments. Econometrica. 65, 557 (1997)